This article has been updated from a previous version to include market research information about Fluidigm from DeciBio.

This story was originally posted on April 20.

Ambry Genetics said today that it has launched genomic research services based on Fluidigm's BioMark HD and Access Array systems.

Ambry Genetics has launched the First-Step Exome test, a sequencing-based test that analyzes the exons and flanking intronic regions of 4,400 genes that are known to be associated with human disease and are defined within the Human Gene Mutation Database.

Ambry Genetics has launched four targeted sequencing-based cancer panels: CancerNext, BreastNext, ColoNext, and OvaNext.

By Monica Heger
As exome sequencing quickly becomes the method of choice for diagnosing rare conditions, a number of academic groups and companies have launched tests in recent months and are reporting their first successes.

This story has been updated to include additional comments from Ambry Genetics and Sigma-Aldrich.
By Justin Petrone

By Monica Heger
2011 will likely be recognized as the year that genome sequencing broke out of the research realm and moved into the clinic.

Ambry Genetics is now offering sequencing services on Illumina's MiSeq instrument. It offers both single- and paired-end sequencing with 50-base pair or 100-base pair reads, as well as indexing and barcoding.


Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.